U.S. Markets open in 2 hrs 45 mins
  • S&P Futures

    4,162.25
    -29.25 (-0.70%)
     
  • Dow Futures

    34,018.00
    -79.00 (-0.23%)
     
  • Nasdaq Futures

    12,683.00
    -163.75 (-1.27%)
     
  • Russell 2000 Futures

    2,006.70
    -1.20 (-0.06%)
     
  • Crude Oil

    75.80
    -0.08 (-0.11%)
     
  • Gold

    1,927.10
    -3.70 (-0.19%)
     
  • Silver

    23.56
    -0.06 (-0.25%)
     
  • EUR/USD

    1.0935
    +0.0024 (+0.2187%)
     
  • 10-Yr Bond

    3.3960
    0.0000 (0.00%)
     
  • Vix

    18.48
    +0.61 (+3.41%)
     
  • GBP/USD

    1.2261
    +0.0032 (+0.2648%)
     
  • USD/JPY

    128.4350
    -0.1690 (-0.1314%)
     
  • BTC-USD

    23,515.09
    -329.63 (-1.38%)
     
  • CMC Crypto 200

    536.75
    -8.57 (-1.57%)
     
  • FTSE 100

    7,834.54
    +14.38 (+0.18%)
     
  • Nikkei 225

    27,509.46
    +107.41 (+0.39%)
     

Why Novavax Shares Are Rising

Novavax, Inc. (NASDAQ: NVAX) shares are trading higher after the company, along with Serum Institute of India, announced the Philippine FDA has granted emergency use authorization for Novavax's COVID-19 vaccine.

"Today's announcement from EMA brings Novavax another step closer to our goal of ensuring broad global access to our protein-based COVID-19 vaccine across Europe," said Stanley C. Erck, President and Chief Executive Officer, Novavax.

"Novavax looks forward to providing an additional vaccine option in Europe, built on a proven, well-understood technology platform, and thanks the European Commission for its ongoing partnership and confidence in our COVID-19 program," Erck stated.

See Also: Iconic Staples Center In Los Angeles To Be Renamed As Crypto.com Arena On Christmas In A Historic Deal

Novavax has a 52-week high of $331.68 and a 52-week low of $85.62.

See more from Benzinga

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.